The FDA has requested withdrawal of BelviqBelviq XR (lorcaserin) by Eisai because a clinical safety trial shows an increased occurrence of pancreatic, colorectal, and lung cancer.  When FDA approved lorcaserin in 2012, they required the drug manufacturer to conduct a clinical trial to evaluate the risk of cardiovascular problems, and a range of cancer types was reported more frequently in the lorcaserin group.  FDA MedWatch